Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory multifactorial disorder affecting approximately 1% of population, with over 3000000 new cases annually. The principal pharmacological agents are nonsteroidal anti-inflammatory drugs (NSAID). Patients with rheumatoid arthritis are vulnerable to NSAID-associated gastrointestinal complications. Based on these findings we developed a new NSAID agent based on phenolic glycoside structure methyl (4-О-β-glucopyranosyloxy)-benzoic acid. In this study we evaluated the methyl (4-О-β-glucopyranosyloxy)-benzoic acid therapeutic effect in adjuvant-induced rat arthritis compared to etoricoxib effect. According to the results, methyl (4-О-β-glucopyranosyloxy)-benzoic acid activity was superior to etoricoxib, paw volume returned to the initial value 2 days early, than it did in etoricoxib group. Therefore, methyl (4-О-β-glucopyranosyloxy)-benzoic acid might contest to the modern antirheumatic drug etoricoxib.
| Original language | English |
|---|---|
| Pages (from-to) | 79-82 |
| Number of pages | 4 |
| Journal | Jurnal Teknologi |
| Volume | 78 |
| Issue number | 6-8 |
| DOIs | |
| Publication status | Published - 1 Jan 2016 |
Fingerprint
Keywords
- Adjuvant arthritis
- NSAID
- Phenolic glycosides
- Rheumatoid arthritis
ASJC Scopus subject areas
- Engineering(all)
Cite this
New antirheumatic substance based on phenolic glycoside structure methyl (4-O-B-glucopyranosyloxy)-benzoic acid. / Alexey, Nemtsev; Ivan, Smirnov; Tatyana, Murashko; Alexey, Ivanov; Alex, Bondarev; Vladimir, Udut.
In: Jurnal Teknologi, Vol. 78, No. 6-8, 01.01.2016, p. 79-82.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - New antirheumatic substance based on phenolic glycoside structure methyl (4-O-B-glucopyranosyloxy)-benzoic acid
AU - Alexey, Nemtsev
AU - Ivan, Smirnov
AU - Tatyana, Murashko
AU - Alexey, Ivanov
AU - Alex, Bondarev
AU - Vladimir, Udut
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Rheumatoid arthritis (RA) is a chronic inflammatory multifactorial disorder affecting approximately 1% of population, with over 3000000 new cases annually. The principal pharmacological agents are nonsteroidal anti-inflammatory drugs (NSAID). Patients with rheumatoid arthritis are vulnerable to NSAID-associated gastrointestinal complications. Based on these findings we developed a new NSAID agent based on phenolic glycoside structure methyl (4-О-β-glucopyranosyloxy)-benzoic acid. In this study we evaluated the methyl (4-О-β-glucopyranosyloxy)-benzoic acid therapeutic effect in adjuvant-induced rat arthritis compared to etoricoxib effect. According to the results, methyl (4-О-β-glucopyranosyloxy)-benzoic acid activity was superior to etoricoxib, paw volume returned to the initial value 2 days early, than it did in etoricoxib group. Therefore, methyl (4-О-β-glucopyranosyloxy)-benzoic acid might contest to the modern antirheumatic drug etoricoxib.
AB - Rheumatoid arthritis (RA) is a chronic inflammatory multifactorial disorder affecting approximately 1% of population, with over 3000000 new cases annually. The principal pharmacological agents are nonsteroidal anti-inflammatory drugs (NSAID). Patients with rheumatoid arthritis are vulnerable to NSAID-associated gastrointestinal complications. Based on these findings we developed a new NSAID agent based on phenolic glycoside structure methyl (4-О-β-glucopyranosyloxy)-benzoic acid. In this study we evaluated the methyl (4-О-β-glucopyranosyloxy)-benzoic acid therapeutic effect in adjuvant-induced rat arthritis compared to etoricoxib effect. According to the results, methyl (4-О-β-glucopyranosyloxy)-benzoic acid activity was superior to etoricoxib, paw volume returned to the initial value 2 days early, than it did in etoricoxib group. Therefore, methyl (4-О-β-glucopyranosyloxy)-benzoic acid might contest to the modern antirheumatic drug etoricoxib.
KW - Adjuvant arthritis
KW - NSAID
KW - Phenolic glycosides
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84975042666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975042666&partnerID=8YFLogxK
U2 - 10.11113/jt.v78.9058
DO - 10.11113/jt.v78.9058
M3 - Article
VL - 78
SP - 79
EP - 82
JO - Jurnal Teknologi (Sciences and Engineering)
JF - Jurnal Teknologi (Sciences and Engineering)
SN - 0127-9696
IS - 6-8
ER -